The Finance Insider blog

Search This Blog

Blog Archive

The Finance Insider

Monday, April 7, 2014

Sun Pharmaceutical Industries has agreed to acquire Ranbaxy Laboratories.

Fellow Indian company Ranbaxy Laboratories for $3.2B in an all-stock deal that will create the world's fifth-largest generic-drug maker. The merger combines two firms that have had problems with quality issues. Ranbaxy, which is owned by Japan's Daiichi Sankyo (OTCPK:DSKYF), is banned from selling ingredients to the U.S., while Sun's Karkhadi facility is also not allowed to export products to the U.S.

No comments:

Post a Comment